# GSK positive CHMP opinion recommending Jemperli plus chemotherapy to treat endometrial cancer

- Link: https://www.directorstalkinterviews.com/gsk-positive-chmp-opinion-recommending-jemperli-plus-chemotherapy-to-treat-endometrial-cancer/4121129854
- Published: 2023-10-16T07:10:56+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
LON/NYSE: GSK) has announced the Committee for Medicinal Products for Human Use (
CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending
approval of _Jemperli_ (dostarlimab) in combination with carboplatin-paclitaxel (
chemotherapy), for the treatment of adult patients with mismatch repair deficient(
dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial
cancer and who are candidates for systemic therapy. The CHMP opinion is one of the
final steps prior to a marketing authorisation decision by the European Commission.

·   If approved, dostarlimab would become the first new frontline treatment option
in the European Union (EU) in decades and the only immuno-oncology combination regimen
available for this patient population with high unmet need

·   Decision on EU marketing authorisation expected by the end of the year

> **Hesham Abdullah,** **Senior Vice President,** **Global** **Head Oncology, R&
> D,** **GSK, said:** “We are pleased with this positive CHMP opinion and the potential
> for dostarlimab with chemotherapy to treat patients with this very challenging
> form of endometrial cancer. If approved, dostarlimab plus chemotherapy will be
> the first new treatment option in decades for these patients in the European Union,
> offering long-awaited new hope for improved long-term outcomes. This opinion further
> reinforces our confidence in dostarlimab’s important role in the immuno-oncology
> treatment landscape.”

GSK’s application for the authorisation of dostarlimab is based on interim analysis
results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial, which were
presented (https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-clinical-
trial-demonstrates-potential-of-jemperli-plus-chemotherapy-to-redefine-the-treatment-
of-primary-advanced-or-recurrent-endometrial-cancer/) at the European Society for
Medical Oncology (ESMO) Virtual Plenary and Society of Gynecologic Oncology (SGO)
Annual Meeting on 27 March 2023, and simultaneously published in _The New England
Journal of Medicine._ The trial results reflect a robust median duration of follow-
up of ≥ 25 months. Part 1 of the RUBY trial met its primary endpoint of investigator-
assessed progression-free survival (PFS) in patients treated with dostarlimab plus
carboplatin and paclitaxel in the dMMR/MSI-H population. In the dMMR/MSI-H population,
a 72% reduction in the risk of disease progression or death was observed (HR: 0.28[
95% CI: 0.16-0.50]).

In a prespecified, exploratory analysis of overall survival (OS) in the dMMR/MSI-
H population, the addition of dostarlimab to chemotherapy resulted in a 70% reduction
in the risk of death relative to chemotherapy alone (HR: 0.30 [95% CI: 0.13-0.70]).

The safety and tolerability profile for dostarlimab plus carboplatin and paclitaxel
was generally consistent with the known safety profiles of the individual agents.
The most common adverse reactions (≥ 10%) in patients receiving dostarlimab plus
chemotherapy were rash, hypothyroidism (overactive thyroid), increased alanine aminotransferase
or increased aspartate aminotransferase (increased liver enzyme levels in the blood),
pyrexia (fever) and dry skin.

This opinion follows the July 2023 expansion of the label for _Jemperli_ in the 
US to include this indication (https://www.gsk.com/en-gb/media/press-releases/jemperli-
plus-chemotherapy-approved-in-us-for-new-indication/). The new indication for _Jemperli_
was reviewed under the FDA Oncology Center of Excellence Project Orbis framework,
which allowed for concurrent submission to and review by US and other international
regulatory authorities. As part of Project Orbis, _Jemperli_ was also approved in
the United Kingdom earlier this month in combination with platinum-containing chemotherapy
for the treatment of adult patients with dMMR/MSI-H primary advanced or recurrent
endometrial cancer and who are candidates for systemic therapy. The application 
remains under review in Australia, Canada, Switzerland and Singapore.

In the EU, _Jemperli_ currently has conditional approval as a monotherapy for treating
adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has
progressed on or following prior treatment with a platinum-containing regimen. If
the European Commission approves the frontline indication for _Jemperli_ + chemotherapy,
this conditional approval is expected to be converted to full approval at the same
time. A decision is expected by the end of this year.

Share on:
